Table 2.

Subgroup analysis for high vs. low salt intake and the risk of gastric cancer.

Group	RR and 95%CI	P-value	Heterogeneity (%)	P-value for heterogeneity	Ratio between subgroups	P-value for interaction test
Country
US or Europe	1.16 (0.96–1.40)	0.130	0.0	0.706	0.88 (0.68–1.13)	0.315
Asia	1.32 (1.11–1.55)	0.001	69.0	0.001
Gender
Men	1.10 (1.03–1.17)	0.002	0.0	0.812	1.01 (0.88–1.16)	0.898
Women	1.09 (0.96–1.23)	0.171	0.0	0.750
Outcomes
GC incidence	1.14 (1.05–1.25)	0.003	25.0	0.222	0.60 (0.39–0.93)	0.022
GC mortality	1.89 (1.24–2.89)	0.003	50.6	0.108
Follow-up duration (years)
≥ 10.0	1.38 (1.12–1.69)	0.002	57.6	0.015	1.25 (1.01–1.55)	0.037
<10.0	1.10 (1.04–1.16)	<0.001	0.0	0.692
Adjusted educational
Yes	1.23 (1.06–1.42)	0.006	0.0	0.866	0.95 (0.76–1.18)	0.626
No	1.30 (1.10–1.54)	0.003	65.0	0.002
Adjusted BMI
Yes	1.32 (1.03–1.69)	0.026	79.0	0.003	1.07 (0.81–1.43)	0.630
No	1.23 (1.07–1.43)	0.004	22.2	0.246
Adjusted alcohol
Yes	1.21 (1.01–1.46)	0.036	65.9	0.012	0.93 (0.72–1.20)	0.581
No	1.30 (1.09–1.55)	0.003	28.1	0.214
Adjusted smoking
Yes	1.22 (1.04–1.42)	0.015	55.9	0.026	0.92 (0.70–1.22)	0.583
No	1.32 (1.04–1.66)	0.020	48.2	0.103
Adjusted PA
Yes	1.24 (1.01–1.52)	0.038	72.7	0.005	0.98 (0.75–1.26)	0.856
No	1.27 (1.09–1.49)	0.002	19.6	0.275

RR, relative risk; CI, confidence interval; GC, gastric cancer; BMI, body mass index; PA, physical activity.